Etoposide — Drug Intelligence | 113 EU Trials

Filter these 113 trials by condition, phase, country and more.

Open in Search →

113 Registered trials

56 Recruiting

41 Completed trials

83 Sponsors

26 Countries

Phase III

Phase II

Phase III: 43 Phase II/III: 7 Phase II: 49 Phase I/II: 7 Phase III/IV: 1 Phase IV: 4 Phase I (Other): 1 Phase I (FiH): 1

Oversight events:

3 serious breaches 25 temporary halts 5 urgent safety measures 1 unexpected event 5 corrective measures across 11 trials

View oversight register →

Indications tested

Small cell lung cancer extensive stage 9 Neuroblastoma 3 Diffuse large B-cell lymphoma 3 Ewing's sarcoma 2 Small cell lung cancer 2 High-grade B-cell lymphoma 2 Non-small cell lung cancer 2 Small cell lung cancer metastatic 2 Small cell lung cancer limited stage 2 Breast cancer metastatic 2 Primary mediastinal large B-cell lymphoma 2 Breast cancer female 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 8 GPOH gGmbH 6 Assistance Publique Hopitaux De Paris 5 Institut Curie 4 Novartis Pharma AG 4 AstraZeneca AB 3 Centre Leon Berard 3 Kite Pharma Inc. 3 The University Of Birmingham 3 University Of Cologne 3 Amgen Inc. 2 Association Gercor 2

All trials — page 3

113 total

Tucatinib in combination with Oral Etoposide (VP16) and Trastuzumab in Patients with metastatic HER2+ Breast cancer (TUC-TOC) Recruiting

2022-500743-20-00 Phase II 1 country Institut Curie
Phase II, open label, single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment naïve advanced meR… Recruiting

2022-500988-12-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting

2023-504999-25-00 Phase III 12 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting

2022-501710-62-02 Phase IV 2 countries Lysarc
EDEN : Etude de désescalade thérapeutique et d'évaluation du marqueur miRNA M371 pour les séminomes de stade IIa/IIb < 3 cm Recruiting

2024-514636-25-00 Phase II 1 country Centre Leon Berard
A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors (VAPOR (GETUG T06)) Recruiting

2023-505040-19-00 Phase II 1 country Institut Gustave Roussy
Phase 2 trial of Translational approach to first line cHemoimmunotherapy followed by maintenance with pembrOlizumab and olaparib in Extensiv… Recruiting

2024-514666-39-00 Phase II 1 country Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting

2022-500783-35-00 Phase III 6 countries GPOH gGmbH
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Che… Recruiting

2023-504264-41-00 Phase I/II 8 countries F. Hoffmann-La Roche AG
MetroWilms Recruiting

2022-502687-20-00 Phase II 1 country Centre Oscar Lambret
Immunological variables associated to ICI toxicity in cancer patients Recruiting

2023-505360-11-00 Phase II 1 country Institut Jules Bordet
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma Recruiting

2022-501180-40-00 Phase III 8 countries GPOH gGmbH
Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line small cell ov… Recruiting

2024-515310-40-01 Phase II 1 country Asso De Recherche Cancers Gynecologiques
RETINO 2018: conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome Recruiting

2024-514025-30-00 Phase II 1 country Institut Curie
An international trial for children with atypical teratoid/rhabdoid tumours (ATRT) Recruiting

2022-501456-28-00 Phase III 12 countries GPOH gGmbH
SIOP RANDOMET 2017 Recruiting

2023-508926-91-00 Phase III 10 countries GPOH gGmbH
Randomised trial evaluating mifamurtide in combination with standard chemotherapy in patients with high-grade osteosarcoma at high risk of r… Recruiting

2024-514780-26-00 Phase II 1 country Unicancer
Paediatric Hepatic International Tumour Trial Recruiting

2024-516110-38-00 Phase III 10 countries The University Of Birmingham
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting

2023-506987-15-00 Phase I/II 11 countries Merck Sharp & Dohme LLC
SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependym… Recruiting

2024-512222-28-00 Phase II/III 13 countries Centre Leon Berard
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma Recruiting

2024-516078-31-00 Phase II/III 10 countries The University Of Birmingham
MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial Recruiting

2024-515626-92-00 Phase II 7 countries Medical University Of Vienna
NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years Recruiting

2024-518254-16-00 Phase III 7 countries Vaestra Goetalandsregionen
Conservative treatment of patients with retinoblastoma Recruiting

2024-517275-21-00 Phase II 1 country Institut Curie

Showing 49–72 of 113 trials

← All drugs A–Z